Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma
NCT02419560Phase 1Completed
- Start
- Apr 2015
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in mantle cell lymphoma (MCL). Primary endpoint: Incidence of Dose Limiting Toxicities at 30 days. Started Apr 2015; status: completed.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02419560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419560.